TRACON Pharmaceuticals, Inc (TCON): Rasio rega marang prakiraan pendapatan
TRACON Pharmaceuticals is expanding its oncology presence by utilizing a clinical trial outsourcing model. The forward P/S valuation demonstrates price dynamics relative to future revenue, where 0.00 captures a new level. The protection of the ENVASARC platform limits competitors but requires capital expenditures for FDA approval. Pragmatic investor sentiment is currently focused on optimizing the company's biotech assets.
Ringkesan rincian data analitis TRACON Pharmaceuticals, Inc (TCON)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal TRACON Pharmaceuticals|TCON - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal TRACON Pharmaceuticals|TCON - Utang kumulatif perusahaan|Utang marang nilai buku TRACON Pharmaceuticals, Inc|TCON - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan TRACON Pharmaceuticals|Rasio cepet traconpharma.com
- data bathi bisnis lan rasio investasi:
TCON - Asil keuangan resik|Proyeksi bathi mangsa ngarep TRACON Pharmaceuticals|TCON - Koefisien rega marang bathi|Pangali Forward P/E TRACON|TCON - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan TRACON Pharmaceuticals, Inc|TCON - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan TRACON Pharmaceuticals|TCON - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan traconpharma.com|TCON - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep TRACON Pharmaceuticals
- data dodolan lan asil:
Analisis wiwitan perusahaan:TRACON Pharmaceuticals, Inc. (TCON)
Forward P/S measures the market value of a company relative to projected revenue, determining the business's margin of safety and the speed at which investor confidence in future cash flows recovers. By analyzing the expected P/S metric on the GURU.Markets platform, an investor assesses the efficiency of the internal clinical trial model of TRACON Pharmaceuticals (TCON), which minimizes contractor costs and enhances the commercialization potential of its drugs.
Pesaing TRACON Pharmaceuticals
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Multiplikator Forward P/S Qiagen NV QGEN|IONS - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan RGEN (Repligen Inc.)|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan crisprtx.com|WGS (GeneDx) - Multiplikator Forward P/S|Multiplikator Forward P/S Ultragenyx Pharmaceutical Inc.|Multiplikator Forward P/S BEAM|Multiplikator forward rega marang pendapatan Sarepta Corp SRPT|Multiplikator Forward P/S TWST (Twist Bioscience)|10xgenomics.com (TXG) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NTLA: Multiplikator forward rega marang pendapatan|STOK - Multiplikator Forward P/S|BLFS (BioLife Corp) - Multiplikator forward rega marang pendapatan|WVE: Rasio rega marang pendapatan sing dikarepake|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|sionnatx.com (SION) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S PRME|Multiplikator forward rega marang pendapatan Taysha Gene Therapies Inc TSHA|Multiplikator Forward P/S QURE (uniQure Corp)|Multiplikator Forward P/S MeiraGTx Corp MGTX|RGNX - Rasio rega marang prakiraan pendapatan|SLDB: Rasio rega marang prakiraan pendapatan|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|PACB - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan BNTC|DSGN (Design Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S RCKT|Multiplikator forward rega marang pendapatan 4dmoleculartherapeutics.com FDMT|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. (KRRO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|EDIT - Rasio rega marang prakiraan pendapatan|SLN (Silence Therapeutics Corp) - Kapitalisasi marang prakiraan pendapatan|PRQR: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CDXS|Rasio rega marang prakiraan pendapatan Sangamo Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan NAUT (Nautilus Biotechnology Inc)|Multiplikator Forward P/S MGX|Multiplikator Forward P/S Precision BioSciences Inc. (DTIL)|Generation Bio - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake BOLD (boundlessbio.com)|XCUR - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan IMNN (Imunon, Inc.)|PHIO: Multiplikator Forward P/S|Mustang Bio (MBIO) - Multiplikator Forward P/S|RNAZ (TransCode Therapeutics Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Bionano (BNGO)|Rasio rega marang prakiraan pendapatan Applied DNA Sciences, Inc. (APDN)|BLUE - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan ImmunoPrecise Antibodies Ltd. IPA|OMGA: Kapitalisasi marang prakiraan pendapatan|OMIC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan RGLS (regulusrx.com)|Syros Pharmaceuticals, Inc. (SYRS) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TBIO (Telesis Bio Inc.)|UBX (Unity Bio) - Multiplikator Forward P/S
